The blocking antibodies for Siglec-7, Siglec-9, and Siglec-15 exhibit the ability to restore anti-tumor immunity and reduce tumor burden in vivo, making them potential alternative treatments for cancer patients resistant to the well-known PD-L1/PD-1 blockades [132,133,135,156,157]. This evidence concerns the gene CD274 and cancer.